Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-80 years old, male and female~2. Without anti-cancer treatment before randomization, ECOG score 0-2~3. Estimate to bear at least 4 cycles chemotherapy treatment with normal function of heart, lungs, liver and kidneys.~4. Survival expectation ≥6 months~5. Signed Informed Consent Form, willing to follow all study procedures~Exclusion Criteria:~1. Received chemotherapy treatment within 4 weeks before randomization.~2. Current peripheral neuropathy(by chemotherapy, diabetes mellitus, alcoholic disease) and relative symptoms with relevant treatment.~3. Concurrent treatment within 30 days after randomization with the following drugs: Calcium-Magnesium injection, glutathione, and similar ingredients with PerOx Quench (such as polyene phosphatidyl choline).~4. Laboratory tests found not suitable for chemotherapy patients (Absolute neutrophil count \<2.0×10\*9/L\<2,000/mm3\>; or platelet count\<100× 10\*9/L\<100,000/mm3\>; or hemoglobin \<10/dl; or serum total bilirubin \>2 Upper Limit Of Normal (ULN), alanine aminotransferase (ALT)/aspartate aminotransferase (AST)\>3 Upper Limit Of Normal (ULN); or serum creatinine \>1.5 Upper Limit Of Normal (ULN) \<or creatinine clearance rate~   ≤60ml/min\>）.~5. Pregnancy, lactation and reluctant to using contraception women.~6. Patients with symptomatic brain metastases and other mental disorders could not be self assessment.~7. Alcohol and/or drug abuse or doctors determine compliance's claim.~8. Within a month in other clinical trial subjects.~9. Once into the group of this study, or random within eight weeks before using this product.~10. personnel involved this study.~11. Not completed independent self assessment of patients.~12. Other researchers determine does not fit to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PerOx Arm (Type: EXPERIMENTAL): PerOx Quench arm 4g/sachet each time by water, q6h
- Comparative Arm (Type: PLACEBO_COMPARATOR): PerOx Quench placebo 4g/sachet each time by water, q6h

Based on this trial design, predict the completion outcome and termination type (if applicable).